Caricamento...
Pulse afatinib for ERBB2 exon 20 insertion mutated lung adenocarcinomas
INTRODUCTION: Genomic aberrations involving erb-b2 receptor tyrosine kinase 2 (ERBB2) are driver oncogenes in ∼2% of lung adenocarcinomas. However, the use of daily dosing of ERBB2 tyrosine kinase inhibitors (TKIs) - including afatinib - has been fraught by plasma concentrations that barely achieve...
Salvato in:
| Pubblicato in: | J Thorac Oncol |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4877224/ https://ncbi.nlm.nih.gov/pubmed/26964772 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2016.02.016 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|